Limited availability of EGFR strongly positive mouse tumorigenic cancer lines (and no such melanoma cells) hinders the use of this convenient variant for the next-step preliminary in vivo testing via in vitro screening EGFR-targeted agents. The gene discussed is EGFR; the disease is cancer.